Showing 2711-2720 of 5909 results for "".
- Members of Congress Urge Leaders to Act to Protect Patient Access to Surgical Care and Stop Medicare Cutshttps://modernod.com/news/members-of-congress-urge-leaders-to-act-to-protect-patient-access-to-surgical-care-and-stop-medicare-cuts/2478433/A group of 229 Representatives sent a letter
- STRAP Technologies Announces Device to Aid the Visually Impairedhttps://modernod.com/news/strap-technologies-announces-device-to-aid-the-visually-impaired/2478430/STRAP Technologies announced the creation of a hands-free device designed to be worn by the visually impaired to allow for more independence and mobility. STRAP is a wearable, hands-free device with an array of sensors that work by sending real-time information that detect obstacles at the
- Coherent Ships 5,000th OEM ExciStar Devicehttps://modernod.com/news/coherent-ships-5000th-oem-excistar-device/2478427/Coherent recently delivered the 5,000th OEM ExciStar laser for refractive corneal surgery. “The longevity of the laser components and the excellent pulse stability at the ultra-short 193 nm laser wavelength have made the ExciStar family the ideal ablation source for ever faster and m
- CVS, Walgreens Make Deal With Trump Admin to Quickly Distribute COVID-19 Vaccines to Nursing Homeshttps://modernod.com/news/cvs-walgreens-make-deal-with-trump-admin-to-quickly-distribute-covid-19-vaccines-to-nursing-homes/2478429/Retail pharmacy chains CVS Health and Walgreens reached a deal with the Trump administration to quickly provide and administer COVID-19 vaccines directly to nursing homes with no out-of-pocket costs, according to a FierceHealthcare
- Concerns Over Surgical Waste Are Clouding Future of Single-Use Device Markethttps://modernod.com/news/concerns-over-surgical-waste-are-clouding-future-of-single-use-device-market/2478423/The global single-use surgical device market has shown steady growth over several decades, reaching a peak of $3.4 billion in 2019, but growing concerns over the amount of waste created by disposable surgical devices have raised questions about future growth prospects, according to a Market Scope
- Oxular Receives Rare Paediatric Disease and Orphan-Drug Designations for Retinoblastoma Treatmenthttps://modernod.com/news/oxular-receives-rare-paediatric-disease-and-orphan-drug-designations-for-retinoblastoma-treatment/2478404/Oxular Limited announces it has received both rare paediatric disease and orphan drug designations from the FDA for OXU-003, the company’s proprietary drug in development for the treatment of retinoblastoma. Retinoblastoma is a rare form of eye cancer that usually develops in early childho
- Tarsus Releases Data from Io and Europa Trials for TP-03 to Treat Demodex Blepharitis and Begins Phase 2b/3 Saturn-1 Trialhttps://modernod.com/news/tarsus-releases-data-from-io-and-europa-trials-for-tp-03-to-treat-demodex-blepharitis-and-begins-phase-2b-3-saturn-1-trial/2478374/Tarsus Pharmaceuticals announced data from its phase 2 trials, Io (a Phase 2a, single-arm open-label trial) and Europa (a Phase 2b, randomized vehicle-controlled trial), evaluating the safety and efficacy of TP-03, a novel ophthalmic therapeutic being developed for t
- Contact Lens Institute Announces The EASY Way Program to Simplify Contact Lens Wear & Carehttps://modernod.com/news/contact-lens-institute-announces-the-easy-way-program-to-simplify-contact-lens-wear-care/2478377/To generate greater consumer familiarity with contact lens health and safety year-round in the United States and Canada, the Contact Lens Institute (CLI) has launched “The EASY Way” (Eyes, Awareness, Safety and You). The program includes simplified
- New Phase 3 Analysis Demonstrates Beovu Showed Improvement in BCVA in Wet AMD Patients With Early Persistent Fluidhttps://modernod.com/news/new-phase-3-analysis-demonstrates-beovu-showed-improvement-in-bcva-in-wet-amd-patients-with-early-persistent-fluid/2478364/Novartis announced that results of two new post-hoc analyses of the phase 3 HAWK and HARRIER clinical trials in wet age-related macular degeneration (AMD) were presented at the Euretina 2020 virtual congress. The first analysis demonstrated fewer Beovu (brolucizumab) patients had early per
- Eyevensys Receives FDA Orphan Drug Designation for EYS611 for Treatment of Retinitis Pigmentosahttps://modernod.com/news/eyevensys-receives-fda-orphan-drug-designation-for-eys611-for-treatment-of-retinitis-pigmentosa/2478365/Eyevensys announced that the FDA has granted an orphan-drug designation for EYS611 for the treatment of retinitis pigmentosa (RP). Eyevensys is developing EYS611, a DNA plasmid that encodes for the human transferrin protein, to benefit patients diagnosed with RP, as well as other degenerat